The Filariases

Manson's Tropical Diseases: Twenty-Third Edition

Volumn , Issue , 2013, Pages 737-765

  Simonsen, Paul E ^a   Fischer, Peter U ^b   Hoerauf, Achim ^c   Weil, Gary J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942868211     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7020-5101-2.00055-8     Document Type: Chapter

References (234)

1. Grove DI A history of human helminthology 1990, CABI, Wallingford.
2. Fischer K, Beatty WL, Jiang D, et al. Tissue and stage-specific distribution of Wolbachia in Brugia malayi. PLoS Negl Trop Dis 2011, 5:e1174.
3. Slatko BE, Taylor MJ, Foster JM The Wolbachia endosymbiont as an anti-filarial nematode target. Symbiosis 2010, 51:55-65.
4. WHO Lymphatic filariasis: Progress report 2000-2009 and strategic plan 2010-20 2010, World Health Organization, Geneva.
5. Michael E, Bundy DA Global mapping of lymphatic filariasis. Parasitol Today 1997, 13:472-476.
6. Cheun HI, Lee JS, Cho SH, et al. Elimination of lymphatic filariasis in the Republic of Korea: an epidemiological survey of formerly endemic areas, 2002-2006. Trop Med Int Health 2009, 14:445-449.
7. Sudomo M, Chayabejara S, Duong S, et al. Elimination of lymphatic filariasis in Southeast Asia. Adv Parasitol 2010, 72:205-233.
8. Figueredo-Silva J, Noroes J, Addiss D, et al. Sex ratio of Wuchereria bancrofti in surgical specimens from an endemic area of Brazil. Ann Trop Med Parasitol 2008, 102:229-238.
9. Simonsen PE, Niemann L, Meyrowitsch DW Wuchereria bancrofti in Tanzania: microfilarial periodicity and effect of blood sampling time on microfilarial intensities. Trop Med Int Health 1997, 2:153-158.
10. Simonsen PE, Meyrowitsch DW, Jaoko WG, et al. Bancroftian filariasis infection, disease and specific antibody response patterns in a high and a low endemicity community in East Africa. Am J Trop Med Hyg 2002, 66:550-559.
11. Rwegoshora RT, Simonsen PE, Meyrowitsch DW, et al. Bancroftian filariasis: house-to-house variation in the vectors and transmission - and the relationship to human infection - in an endemic community of coastal Tanzania. Ann Trop Med Parasitol 2007, 101:51-60.
12. Bockarie MJ, Pedersen EM, White GB, et al. Role of vector control in the global program to eliminate lymphatic filariasis. Annu Rev Entomol 2009, 54:469-487.
13. Fischer P, Supali T, Maizels RM Lymphatic filariasis and Brugia timori: prospects for elimination. Trends Parasitol 2004, 20:351-355.
14. Meyrowitsch DW, Simonsen PE, Magesa SM A 26-year follow-up of bancroftian filariasis in two communities in north-eastern Tanzania. Ann Trop Med Parasitol 2004, 98:155-169.
15. Alexander ND, Grenfell BT The effect of pregnancy on Wuchereria bancrofti microfilarial load in humans. Parasitology 1999, 119(Pt 2):151-156.
16. Lammie PJ, Hitch WL, Walker Allen EM, et al. Maternal filarial infection as risk factor for infection in children. Lancet 1991, 337:1005-1006.
17. Meyrowitsch DW, Simonsen PE, Garred P, et al. Association between mannose-binding lectin polymorphisms and Wuchereria bancrofti infection in two communities in North-Eastern Tanzania. Am J Trop Med Hyg 2010, 82:115-120.
18. Babu S, Bhat SQ, Pavan Kumar N, et al. Filarial lymphedema is characterized by antigen-specific Th1 and th17 proinflammatory responses and a lack of regulatory T cells. PLoS Negl Trop Dis 2009, 3(4):e420.
19. Babu S, Blauvelt CP, Kumaraswami V, et al. Regulatory networks induced by live parasites impair both Th1 and Th2 pathways in patent lymphatic filariasis: implications for parasite persistence. J Immunol 2006, 176:3248-3256.
20. Babu S, Kumaraswami V, Nutman TB Alternatively activated and immunoregulatory monocytes in human filarial infections. J Infect Dis 2009, 199:1827-1837.
21. Maizels RM, Pearce EJ, Artis D, et al. Reg-ulation of pathogenesis and immunity in helminth infections. J Exp Med 2009, 206:2059-2066.
22. Metenou S, Dembele B, Konate S, et al. Filarial infection suppresses malaria-specific multifunctional Th1 and Th17 responses in malaria and filarial coinfections. J Immunol 2011, 186:4725-4733.
23. Nookala S, Srinivasan S, Kaliraj P, et al. Impairment of tetanus-specific cellular and humoral responses following tetanus vaccination in human lymphatic filariasis. Infect Immun 2004, 72:2598-2604.
24. Michael E, Grenfell BT, Bundy DA The association between microfilaraemia and disease in lymphatic filariasis. Proc Biol Sci 1994, 256:33-40.
25. Freedman DO Immune dynamics in the pathogenesis of human lymphatic filariasis. Parasitol Today 1998, 14:229-234.
26. Jaoko WG, Simonsen PE, Meyrowitsch DW, et al. Filarial-specific antibody response in East African bancroftian filariasis: effects of host infection, clinical disease and filarial endemicity. Am J Trop Med Hyg 2006, 75:97-107.
27. Dreyer G, Medeiros Z, Netto MJ, et al. Acute attacks in the extremities of persons living in an area endemic for bancroftian filariasis: differentiation of two syndromes. Trans R Soc Trop Med Hyg 1999, 93:413-417.
28. Debrah AY, Mand S, Specht S, et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathogens 2006, 2:e92.
29. Bennuru S, Nutman TB Lymphangiogenesis and lymphatic remodeling induced by filarial parasites: implications for pathogenesis. PLoS Pathol 2009, 5:e1000688.
30. Taylor MJ Wolbachia in the inflammatory pathogenesis of human filariasis. Ann N Y Acad Sci 2003, 990:444-449.
31. Dreyer G, Addiss D, Gadelha P, et al. Interdigital skin lesions of the lower limbs among patients with lymphoedema in an area endemic for bancroftian filariasis. Trop Med Int Health 2006, 11:1475-1481.
32. Olszewski WL, Jamal S, Manokaran G, et al. Bacteriological studies of blood, tissue fluid, lymph and lymph nodes in patients with acute dermatolymphangioadenitis (DLA) in course of 'filarial' lymphedema. Acta Trop 1999, 73:217-224.
33. Noroes J, Addiss D, Cedenho A, et al. Pathogenesis of filarial hydrocele: risk associated with intrascrotal nodules caused by death of adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 2003, 97:561-566.
34. Noroes J, Dreyer G A mechanism for chronic filarial hydrocele with implications for its surgical repair. PLoS Negl Trop Dis 2010, 4:e695.
35. Weil GJ, Ramzy RM, El Setouhy M, et al. A longitudinal study of Bancroftian filariasis in the Nile Delta of Egypt: baseline data and one-year follow-up. Am J Trop Med Hyg 1999, 61:53-58.
36. Wartman WB Filariasis in American armed forces in World. War II. Medicine (Baltimore) 1947, 26:333-394.
37. Dreyer G, Addiss D, Roberts J, et al. Progression of lymphatic vessel dilatation in the presence of living adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 2002, 96:157-161.
38. Freedman DO, de Almeida Filho PJ, Besh S, et al. Lymphoscintigraphic analysis of lymphatic abnormalities in symptomatic and asymptomatic human filariasis. J Infect Dis 1994, 170:927-933.
39. Bernhard P, Makunde RW, Magnussen P, et al. Genital manifestations and reproductive health in female residents of a Wuchereria bancrofti-endemic area in Tanzania. Trans R Soc Trop Med Hyg 2000, 94:409-412.
40. Dunyo SK, Nkrumah FK, Ahorlu CK, et al. Exfoliative skin manifestations in acute lymphatic filariasis. Trans R Soc Trop Med Hyg 1998, 92:539-540.
41. McMahon JE, Magayauka SA, Kolstrup N, et al. Studies on the transmission and prevalence of Bancroftian filariasis in four coastal villages of Tanzania. Ann Trop Med Parasitol 1981, 75:415-431.
42. Hussein O, El Setouhy M, Ahmed ES, et al. Duplex Doppler sonographic assessment of the effects of diethylcarbamazine and albendazole therapy on adult filarial worms and adjacent host tissues in Bancroftian filariasis. Am J Trop Med Hyg 2004, 71:471-477.
43. Simonsen PE, Bernhard P, Jaoko WG, et al. Filaria dance sign and subclinical hydrocele in two east African communities with bancroftian filariasis. Trans R Soc Trop Med Hyg 2002, 96:649-653.
44. Mand S, Debrah AY, Klarmann U, et al. The role of ultrasonography in the differentiation of the various types of filaricele due to bancroftian filariasis. Acta Trop 2011, 120(Suppl 1):S23-S32.
45. Dunyo SK, Ahorlu CK, Simonsen PE Scarification as a risk factor for rapid progression of filarial elephantiasis. Trans R Soc Trop Med Hyg 1997, 91:446.
46. WHO Lymphatic filariasis: the disease and its control. Fifth report of the WHO Expert Committee on Filariasis. World Health Organ Tech Rep Ser 1992, 821:1-71.
47. Dreyer G, Addiss D, Dreyer P, et al. Basic Lymphoedema management, Treatment and Prevention of Problems Associated with Lymphatic Filariasis 2002, Hollis, New Hampshire.
48. Gulati S, Gupta N, Singh NP, et al. Chyluria with proteinuria or filarial nephropathy? An enigma. Parasitol Int 2007, 56:251-254.
49. Dreyer G, Dreyer P, Piessens WF Extralymphatic disease due to bancroftian filariasis. Braz J Med Biol Res 1999, 32:1467-1472.
50. Ottesen EA, Nutman TB Tropical pulmonary eosinophilia. Annu Rev Med 1992, 43:417-424.
51. Sarker PC, Khandker HH, Sarker CR, et al. Clinico-laboratory profile of 45 filarial arthritis cases. Mymensingh Med J 2007, 16:S7-11.
52. Witt C, Ottesen EA Lymphatic filariasis: an infection of childhood. Trop Med Int Health 2001, 6:582-606.
53. Shenoy RK, Bockarie MJ Lymphatic filariasis in children: clinical features, infection burdens and future prospects for elimination. Parasitology 2011, 138:1559-1568.
54. Shenoy RK, Suma TK, Kumaraswami V, et al. Antifilarial drugs, in the doses employed in mass drug administrations by the Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in children with Brugia malayi infection. Ann Trop Med Parasitol 2009, 103:235-247.
55. Magnussen P, Makunde W, Simonsen PE, et al. Chronic pulmonary disorders, including tropical pulmonary eosinophilia, in villages with endemic lymphatic filariasis in Tanga region and in Tanga town, Tanzania. Trans R Soc Trop Med Hyg 1995, 89:406-409.
56. Kazura JW, Bockarie M, Alexander N, et al. Transmission intensity and its relationship to infection and disease due to Wuchereria bancrofti in Papua New Guinea. J Infect Dis 1997, 176:242-246.
57. Davey G, Tekola F, Newport MJ Podoconiosis: non-infectious geochemical elephantiasis. Trans R Soc Trop Med Hyg 2007, 101:1175-1180.
58. McMahon JE, Marshall TF, Vaughan JP, et al. Bancroftian filariasis: a comparison of microfilariae counting techniques using counting chamber, standard slide and membrane (nuclepore) filtration. Ann Trop Med Parasitol 1979, 73:457-464.
59. WHO Global Programme to Eliminate Lymphatic Filariasis: Monitoring and epidemiological assessment of mass drug administration - TAS 2011, WHO, Geneva.
60. Mand S, Marfo-Debrekyei Y, Dittrich M, et al. Animated documentation of the filaria dance sign (FDS) in bancroftian filariasis. Filaria J 2003, 2:3.
61. Noroes J, Addiss D, Amaral F, et al. Occurrence of living adult Wuchereria bancrofti in the scrotal area of men with microfilaraemia. Trans R Soc Trop Med Hyg 1996, 90:55-56.
62. Mand S, Supali T, Djuardi J, et al. Detection of adult Brugia malayi filariae by ultrasonography in humans in India and Indonesia. Trop Med Int Health 2006, 11:1375-1381.
63. Pedersen EM, Stolk WA, Laney SJ, et al. The role of monitoring mosquito infection in the Global Programme to Eliminate Lymphatic Filariasis. Trends Parasitol 2009, 25:319-327.
64. Fischer P, Boakye D, Hamburger J Polymerase chain reaction-based detection of lymphatic filariasis. Med Microbiol Immunol 2003, 192:3-7.
65. Williams SA, Laney SJ, Bierwert LA, et al. Development and standardization of a rapid, PCR-based method for the detection of Wuchereria bancrofti in mosquitoes, for xenomonitoring the human prevalence of bancroftian filariasis. Ann Trop Med Parasitol 2002, 96(Suppl 2):S41-S46.
66. Ramzy RM, El Setouhy M, Helmy H, et al. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 2006, 367:992-999.
67. Weil GJ, Ramzy RM Diagnostic tools for filariasis elimination programs. Trends Parasitol 2007, 23:78-82.
68. Weil GJ, Curtis KC, Fischer PU, et al. A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14. Acta Tropica 2011, 120(Suppl 1):S19-S22.
69. Ottesen EA, Duke BO, Karam M, et al. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 1997, 75:491-503.
70. Dreyer G, Addiss D, Santos A, et al. Direct assessment in vivo of the efficacy of combined single-dose ivermectin and diethylcarbamazine against adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 1998, 92:219-222.
71. Simonsen PE, Magesa SM, Meyrowitsch DW, et al. The effect of eight half-yearly single-dose treatments with DEC on Wuchereria bancrofti circulating antigenaemia. Trans R Soc Trop Med Hyg 2005, 99:541-547.
72. Dreyer G, Pires ML, de Andrade LD, et al. Tolerance of diethylcarbamazine by micro-filaraemic and amicrofilaraemic individuals in an endemic area of Bancroftian filariasis, Recife, Brazil. Trans R Soc Trop Med Hyg 1994, 88:232-236.
73. Supali T, Ismid IS, Ruckert P, et al. Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae. Trop Med Int Health 2002, 7:894-901.
74. Cao WC, Van der Ploeg CP, Plaisier AP, et al. Ivermectin for the chemotherapy of bancroftian filariasis: a meta-analysis of the effect of single treatment. Trop Med Int Health 1997, 2:393-403.
75. Ismail MM, Jayakody RL, Weil GJ, et al. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 1998, 92:94-97.
76. Horton J, Witt C, Ottesen EA, et al. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 2000, 121(Suppl):S147-S160.
77. Supali T, Djuardi Y, Pfarr KM, et al. Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin Infect Dis 2008, 46:1385-1393.
78. Turner JD, Mand S, Debrah AY, et al. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin Infect Dis 2006, 42:1081-1089.
79. Taylor MJ, Makunde WH, McGarry HF, et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 2005, 365:2116-2121.
80. Mand S, Pfarr K, Sahoo PK, et al. Macrofilaricidal activity and amelioration of lymphatic pathology in bancroftian filariasis after 3 weeks of doxycycline followed by single-dose diethylcarbamazine. Am J Trop Med Hyg 2009, 81:702-711.
81. Mand S, Debrah AY, Klarmann U, et al. Doxycline improves filarial lymphedema independent of active filarial infection: a randomized controlled trial. Clin Infect Dis 2012, 55:621-630.
82. Kerketta AS, Babu BV, Rath K, et al. A randomized clinical trial to compare the efficacy of three treatment regimens along with footcare in the morbidity management of filarial lymphoedema. Trop Med Int Health 2005, 10:698-705.
83. Ahorlu CK, Dunyo SK, Asamoah G, et al. Consequences of hydrocele and the benefits of hydrocelectomy: a qualitative study in lymphatic filariasis endemic communities on the coast of Ghana. Acta Tropica 2001, 80:215-221.
84. Dreyer G, Noroes J, Addiss D The silent burden of sexual disability associated with lymphatic filariasis. ActaTropica 1997, 63:57-60.
85. Michael E, Malecela-Lazaro MN, Simonsen PE, et al. Mathematical modelling and the control of lymphatic filariasis. Lancet Infect Dis 2004, 4:223-234.
86. Stolk WA, de Vlas SJ, Habbema JD Advances and challenges in predicting the impact of lymphatic filariasis elimination programmes by mathematical modelling. Filaria J 2006, 5:5.
87. Krentel A, Fischer P, Manoempil P, et al. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia. Trop Med Int Health 2006, 11:1731-1740.
88. Mathieu E, Lammie PJ, Radday J, et al. Factors associated with participation in a campaign of mass treatment against lymphatic filariasis, in Leogane, Haiti. Ann Trop Med Parasitol 2004, 98:703-714.
89. WHO Defining the roles of vector control and xenomonitoring in the Global Programme to Eliminate Lymphatic Filariasis 2002, World Health Organization, Geneva.
90. Ottesen EA Lymphatic filariasis: Treatment, control and elimination. Adv Parasitol 2006, 61:395-441.
91. Addiss DG, Louis-Charles J, Roberts J, et al. Feasibility and effectiveness of basic lymphedema management in Leogane, Haiti, an area endemic for bancroftian filariasis. PLoS Negl Trop Dis 2010, 4:e668.
92. WHO Global Programme to eliminate lymphatic filariasis: progress report on mass drug administration, 2010. Wkly Epidemiol Rec/Health Section of the Secretariat of the League of Nations 2011, 86:377-388.
93. WHO Onchocerciasis and Its Control. Report of a WHO Expert Committee on Onchocerciasis Control. WHO Tech Rep Ser 1995, 852:1-104.
94. Basanez MG, Pion SD, Churcher TS, et al. River blindness: a success story under threat?. PLoS Med 2006, 3:e371.
95. Cupp EW, Sauerbrey M, Richards F Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan®) monotherapy. Acta Tropica 2011, 120(Suppl 1):S100-S108.
96. Higazi TB, Filiano A, Katholi CR, et al. Wolbachia endosymbiont levels in severe and mild strains of Onchocerca volvulus. Mol Biochem Parasitol 2005, 141:109-112.
97. Zimmerman PA, Dadzie KY, De Sole G, et al. Onchocerca volvulus DNA probe classification correlates with epidemiologic patterns of blindness. J Infect Dis 1992, 165:964-968.
98. Fischer P, Garms R, Buttner DW, et al. Reduced prevalence of onchocerciasis in Uganda following either deforestation or vector control with DDT. East African Med J 1997, 74:321-325.
99. Fischer P, Kipp W, Bamuhiga J, et al. Parasitological and clinical characterization of Simulium neavei-transmitted onchocerciasis in western Uganda. Trop Med Parasitol 1993, 44:311-321.
100. Makunde WH, Salum FM, Massaga JJ, et al. Clinical and parasitological aspects of itching caused by onchocerciasis in Morogoro, Tanzania. Ann Trop Med Parasitol 2000, 94:793-799.
101. Zimmerman PA, Katholi CR, Wooten MC, et al. Recent evolutionary history of American Onchocerca volvulus, based on analysis of a tandemly repeated DNA sequence family. Mol Biol Evol 1994, 11:384-392.
102. Botto C, Gillespie AJ, Vivas-Martinez S, et al. Onchocerciasis hyperendemic in the Unturan Mountains: the value of recombinant antigens in describing a new transmission area in southern Venezuela. Trans R Soc Trop Med Hyg 1999, 93:25-30.
103. Kale OO Onchocerciasis: the burden of disease. Ann Trop Med Parasitol 1998, 92(Suppl 1):S101-S115.
104. Kirch AK, Duerr HP, Boatin B, et al. Impact of parental onchocerciasis and intensity of transmission on development and persistence of Onchocerca volvulus infection in offspring: an 18 year follow-up study. Parasitology 2003, 127:327-335.
105. Basanez MG, Boussinesq M Population biology of human onchocerciasis. Philos Trans R Soc Lond Biol Sci 1999, 354:809-826.
106. Habbema JD, Alley ES, Plaisier AP, et al. Epidemiological modelling for onchocerciasis control. Parasitol Today 1992, 8:99-103.
107. Ottesen EA Immune responsiveness and the pathogenesis of human onchocerciasis. J Infect Dis 1995, 171:659-671.
108. Turaga PS, Tierney TJ, Bennett KE, et al. Immunity to onchocerciasis: cells from putatively immune individuals produce enhanced levels of interleukin-5, gamma interferon and granulocyte-macrophage colony-stimulating factor in response to Onchocerca volvulus larval and male worm antigens. Infect Immun 2000, 68:1905-1911.
109. Greene BM, Taylor HR, Aikawa M Cellular killing of microfilariae of Onchocerca volvulus: eosinophil and neutrophil-mediated immune serum-dependent destruction. J Immunol 1981, 127:1611-1618.
110. Cooper PJ, Espinel I, Wieseman Mea Human onchoceraisis and tetanus vaccination: impact on the postvaccination antitetanus response. Infect Immunol 1999, 67:5951-5957.
111. Schnoeller C, Rausch S, Pillai S, et al. A helminth immunomodulator reduces allergic and inflammatory responses by induction of IL-10-producing macrophages. J Immunol 2008, 180:4265-4272.
112. Stewart GR, Boussinesq M, Coulson T, et al. Onchocerciasis modulates the immune response to mycobacterial antigens. Clin Exp Immunol 1999, 117:517-523.
113. Hoerauf A, Brattig N Resistance and susceptibility in human onchocerciasis - beyond Th1 vs. Th2. Trends Parasitol 2002, 18:25-31.
114. Korten S, Hoerauf A, Kaifi JT, et al. Low levels of transforming growth factor-beta (TGF-beta) and reduced suppression of Th2-mediated inflammation in hyperreactive human onchocerciasis. Parasitology 2010, 138:35-45.
115. Brattig NW, Tenner-Racz K, Korten S, et al. Immunohistology of ectopic secondary lymph follicles in subcutaneous nodules from patients with hyperreactive onchocerciasis (sowda). Parasitol Res 2010, 107:657-666.
116. Hoerauf A, Kruse S, Brattig NW, et al. The variant Arg110Gln of human IL-13 is associated with an immunologically hyper-reactive form of onchocerciasis (sowda). Microbes Infect 2002, 4:37-42.
117. Van der Lelij A, Rothova A, Stilma JS, et al. Humoral and cell-mediated immune response against human retinal antigens in relation to ocular onchocerciasis. Acta Leiden 1990, 59:271-283.
118. McCarthy JS, Ottesen EA, Nutman TB Onchocerciasis in endemic and nonendemic populations: differences in clinical presentation and immunologic findings. J Infect Dis 1994, 170:736-741.
119. Tawill SA, Gallin M, Erttmann KD, et al. Impaired antibody responses and loss of reactivity to Onchocerca volvulus antigens by HIV-seropositive onchocerciasis patients. Trans R Soc Trop Med Hyg 1996, 90:85-89.
120. Hoerauf A, Büttner DW, Adjei O, et al. Clinical Review - Onchocerciasis. Endosymbiotic Wolbachia bacteria in the worms are targets for a new therapeutic approach. BMJ 2003, 326:207-210.
121. Hoerauf A, Mand S, Adjei O, et al. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 2001, 357:1415-1416.
122. Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000, 355:1242-1243.
123. Taylor MJ, Hoerauf A, Bockarie M Lymphatic filariasis and onchocerciasis. Lancet 2010, 376:1175-1185.
124. Saint Andre A, Blackwell NM, Hall LR, et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science 2002, 295:1892-1895.
125. Keiser PB, Reynolds SM, Awadzi K, et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J Infect Dis 2002, 185:805-811.
126. Brattig N, Büttner DW, Hoerauf A Neutrophil accumulation around Onchocerca worms and chemotaxis of neutrophils are dependent on Wolbachia endobacteria. Microbes Infect 2001, 3:439-446.
127. Tamarozzi F, Halliday A, Gentil K, et al. Onchocerciasis: the role of Wolbachia bacterial endosymbionts in parasite biology, disease pathogenesis and treatment. Clin Microbiol Rev 2011, 24:459-468.
128. Murdoch ME, Asuzu MC, Hagan M, et al. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Ann Trop Med Parasitol 2002, 96:283-296.
129. Murdoch ME, Hay RJ, Mackenzie CD, et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatol 1993, 129:260-269.
130. Darge K, Buttner DW Ivermectin treatment of hyperreactive onchodermatitis (sowda) in Liberia. Trop Med Parasitol 1995, 46:206-212.
131. Abiose A Onchocercal eye disease and the impact of Mectizan treatment. Ann Trop Med Parasitol 1998, 92(Suppl 1):S11-S22.
132. Marin B, Boussinesq M, Druet-Cabanac M, et al. Onchocerciasis-related epilepsy? Prospects at a time of uncertainty. Trends Parasitol 2006, 22:17-20.
133. Kipp W, Burnham G, Bamuhiiga J, et al. The Nakalanga syndrome in Kabarole District, Western Uganda. Am J Trop Med Hyg 1996, 54:80-83.
134. Newell ED, Vyungimana F, Bradley JE Epilepsy, retarded growth and onchocerciasis, in two areas of different endemicity of onchocerciasis in Burundi. Trans R Soc Trop Med Hyg 1997, 91:525-527.
135. Druet-Cabanac M, Boussinesq M, Dongmo L, et al. Review of epidemiological studies searching for a relationship between onchocerciasis and epilepsy. Neuroepidemiology 2004, 23:144-149.
136. Twum-Danso NA Mass treatment of onchocerciasis with ivermectin: should people with epilepsy and/or growth-retardation syndromes be excluded?. Ann Trop Med Parasitol 2004, 98:99-114.
137. Mand S, Marfo-Debrekyei Y, Debrah A, et al. Frequent detection of worm movements in onchocercal nodules by ultrasonography. Filaria J 2005, 4:1.
138. Boatin BA, Toe L, Alley ES, et al. Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods. Parasitology 2002, 125:545-552.
139. Ozoh G, Boussinesq M, Bissek AC, et al. Evaluation of the diethylcarbamazine patch to evaluate onchocerciasis endemicity in Central Africa. Trop Med Int Health 2007, 12:123-129.
140. Bradley JE, Unnasch TR Molecular approaches to the diagnosis of onchocerciasis. Adv Parasitol 1996, 37:57-106.
141. Rodriguez-Perez MA, Dominguez-Vazquez A, Mendez-Galvan J, et al. Antibody detection tests for Onchocerca volvulus: comparison of the sensitivity of a cocktail of recombinant antigens used in the indirect enzyme-linked immunosorbent assay with a rapid-format antibody card test. Trans R Soc Trop Med Hyg 2003, 97:539-541.
142. Lipner EM, Dembele N, Souleymane S, et al. Field applicability of a rapid-format anti-Ov-16 antibody test for the assessment of onchocerciasis control measures in regions of endemicity. J Infect Dis 2006, 194:216-221.
143. Fischer P, Bamuhiiga J, Kilian AH, et al. Strain differentiation of Onchocerca volvulus from Uganda using DNA probes. Parasitology 1996, 112(Pt 4):401-408.
144. Guevara AG, Vieira JC, Lilley BG, et al. Entomological evaluation by pool screen polymerase chain reaction of Onchocerca volvulus transmission in Ecuador following mass Mectizan distribution. Am J Trop Med Hyg 2003, 68(2):222-227.
145. Aziz MA, Diallo S, Diop IM, et al. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet 1982, 2:171-173.
146. Greene BM, Taylor HR, Cupp EW, et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 1985, 313:133-138.
147. Awadzi K, Dadzie K, Klager S, et al. The chemotherapy of onchocerciasis. XIII. Studies with ivermectin in onchocerciasis patients in northern Ghana, a region with long lasting vector control. Trop Med Parasitol 1989, 40:361-366.
148. Chavasse DC, Post RJ, Davies JB, et al. Absence of sperm from the seminal receptacle of female Onchocerca volvulus following multiple doses of ivermectin. Trop Med Parasitol 1993, 44:155-158.
149. Gardon J, Boussinesq M, Kamgno J, et al. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet 2002, 360:203-210.
150. Pacque M, Munoz B, Poetschke G, et al. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet 1990, 336:1486-1489.
151. Wildenburg G, Darge K, Knab J, et al. Lymph nodes of onchocerciasis patients after treatment with ivermectin: reaction of eosinophil granulocytes and their cationic granule proteins. Trop Med Parasitol 1994, 45:87-96.
152. Whitworth JA, Morgan D, Maude GH, et al. Community-based treatment with ivermectin. Lancet 1988, 2:97-98.
153. De Sole G, Awadzi K, Remme J, et al. A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. II. Adverse reactions. Trop Med Parasitol 1989, 40:375-382.
154. Awadzi K Clinical picture and outcome of serious adverse events in the treatment of onchocerciasis. Filaria J 2003, 2(Suppl 1):S6.
155. Mabey D, Whitworth JA, Eckstein M, et al. The effects of multiple doses of ivermectin on ocular onchocerciasis. A six-year follow-up. Ophthalmology 1996, 103:1001-1008.
156. Fischer P, Kipp W, Kabwa P, et al. Onchocerciasis and human immunodeficiency virus in western Uganda: prevalences and treatment with ivermectin. Am J Trop Med Hyg 1995, 53:171-178.
157. Awadzi K, Boakye DA, Edwards G, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004, 98:231-249.
158. Churcher TS, Pion SD, Osei-Atweneboana MY, et al. Identifying sub-optimal responses to ivermectin in the treatment of River Blindness. Proc Natl Acad Sci U S A 2009, 106:16716-16721.
159. Osei-Atweneboana MY, Eng JK, Boakye DA, et al. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007, 369:2021-2029.
160. Osei-Atweneboana MY, Awadzi K, Attah SK, et al. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis 2011, 5:e998.
161. Hoerauf A, Mand S, Volkmann L, et al. Doxycycline in the treatment of human onchocerciasis: kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect 2003, 5:261-273.
162. Hoerauf A, Specht S, Buttner M, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol 2008, 197:295-311.
163. Hoerauf A Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008, 21:673-681.
164. Hoerauf A, Pfarr K, Mand S, et al. Filariasis in Africa - treatment challenges and prospects. Clin Microbiol Infect 2011, 17:977-985.
165. Evans TG Socioeconomic consequences of blinding onchocerciasis in west Africa. Bull World Health Organ 1995, 73:495-506.
166. Vlassoff C, Weiss M, Ovuga EB, et al. Gender and the stigma of onchocercal skin disease in Africa. Soc Sci Med 2000, 50:1353-1368.
167. Kirkwood B, Smith P, Marshall T, et al. Relationships between mortality, visual acuity and microfilarial load in the area of the Onchocerciasis Control Programme. Trans R Soc Trop Med Hyg 1983, 77:862-868.
168. Little MP, Breitling LP, Basanez MG, et al. Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study. Lancet 2004, 363:1514-1521.
169. Boatin BA, Richards FO Control of onchocerciasis. Adv Parasitol 2006, 61:349-394.
170. Boatin B, Molyneux DH, Hougard JM, et al. Patterns of epidemiology and control of onchocerciasis in west Africa. J Helminthol 1997, 71:91-101.
171. Hougard JM, Yameogo L, Seketeli A, et al. Twenty-two years of blackfly control in the onchocerciasis control programme in West Africa. Parasitol Today 1997, 13:425-431.
172. Boatin B The Onchocerciasis Control Programme in West Africa (OCP). Annals of Tropical Medicine and Parasitology 2008, 102(Suppl 1):13-17.
173. Boatin BA, Hougard JM, Alley ES, et al. The impact of Mectizan on the transmission of onchocerciasis. Ann Trop Med Parasitol 1998, 92(Suppl 1):S46-S60.
174. Ogoussan KT, Hopkins A Mectizan® procurement and delivery for onchocerciasis mass drug administration programmes. Acta Tropica 2011, 120(Suppl 1):S173-S176.
175. Ozoh GA, Murdoch ME, Bissek AC, et al. The African Programme for Onchocerciasis Con-trol: impact on onchocercal skin disease. Trop Med Int Health 2011, 16(7):875-883.
176. Gardon J, Gardon-Wendel N, Demanga N, et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997, 350:18-22.
177. Diawara L, Traore MO, Badji A, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and. Senegal. PLoS Negl Trop Dis 2009, 3:e497.
178. Wanji S, Tendongfor N, Esum M, et al. Heterogeneity in the prevalence and intensity of loiasis in five contrasting bioecological zones in Cameroon. Trans R Soc Trop Med Hyg 2003, 97:183-187.
179. Pion SD, Demanou M, Oudin B, et al. Loiasis: the individual factors associated with the presence of microfilaraemia. Ann Trop Med Parasitol 2005, 99:491-500.
180. Zoure HG, Wanji S, Noma M, et al. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Negl Trop Dis 2011, 5:e1210.
181. Boussinesq M Loiasis. Ann Trop Med Parasitol 2006, 100:715-731.
182. Andy JJ, Bishara FF, Soyinka OO Relation of severe eosinophilia and microfilariasis to chronic African endomyocardial fibrosis. Br Heart J 1981, 45:672-680.
183. Klion AD, Vijaykumar A, Oei T, et al. Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infection. J Infect Dis 2003, 187:128-133.
184. Baize S, Wahl G, Soboslay PT, et al. T helper responsiveness in human Loa loa infection; defective specific proliferation and cytokine production by CD4+ T cells from micro-filaraemic subjects compared with amicro-filaraemics. Clin Exp Immunol 1997, 108:272-278.
185. Churchill DR, Morris C, Fakoya A, et al. Clinical and laboratory features of patients with loiasis (Loa loa filariasis) in the U.K. J Infect 1996, 33:103-109.
186. Nutman TB, Miller KD, Mulligan M, et al. Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. J Infect Dis 1986, 154:10-18.
187. Lipner EM, Law MA, Barnett E, et al. Filariasis in travelers presenting to the GeoSentinel Surveillance Network. PLoS Negl Trop Dis 2007, 1:e88.
188. Klion AD, Massougbodji A, Sadeler BC, et al. Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation. J Infect Dis 1991, 163:1318-1325.
189. Dupont A, Zue-N'dong J, Pinder M Common occurrence of amicrofilaraemic Loa loa filariasis within the endemic region. Trans R Soc Trop Med Hyg 1988, 82:730.
190. Fink DL, Kamgno J, Nutman TB Rapid molecular assays for specific detection and quantitation of Loa loa microfilaremia. PLoS Negl Trop Dis 2011, 5:e1299.
191. Burbelo PD, Ramanathan R, Klion AD, et al. Rapid, novel, specific, high-throughput assay for diagnosis of Loa loa infection. J Clin Microbiol 2008, 46:2298-2304.
192. Twum-Danso NA Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J 2003, 2(Suppl 1):S7.
193. Boussinesq M, Gardon J, Gardon-Wendel N, et al. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2003, 2(Suppl 1):S4.
194. Buttner DW, Wanji S, Bazzocchi C, et al. Obligatory symbiotic Wolbachia endobacteria are absent from Loa loa. Filaria J 2003, 2:10.
195. Klion AD, Ottesen EA, Nutman TB Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up. J Infect Dis 1994, 169:604-610.
196. Klion AD, Massougbodji A, Horton J, et al. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. J Infect Dis 1993, 168:202-206.
197. Nutman TB, Miller KD, Mulligan M, et al. Diethylcarbamazine prophylaxis for human loiasis. Results of a double-blind study. N Engl J Med 1988, 319:752-756.
198. Simonsen PE, Onapa AW, Asio SM Mansonella perstans filariasis in Africa. Acta Tropica 2011, 120(Suppl 1):S109-S120.
199. Asio SM, Simonsen PE, Onapa AW Mansonella perstans filariasis in Uganda: patterns of microfilaraemia and clinical manifestations in two endemic communities. Trans R Soc Trop Med Hyg 2009, 103:266-273.
200. Fischer P, Kilian AH, Bamuhiiga J, et al. Prevalence of Mansonella perstans in western Uganda and its detection using the QBC-fluorescence method. Appl Parasitol 1996, 37:32-37.
201. Onapa AW, Simonsen PE, Baehr I, et al. Rapid assessment of the geographical distribution of Mansonella perstans infections in Uganda, by screening schoolchildren for microfilariae. Ann Trop Med Parasitol 2005, 99:383-393.
202. Fux CA, Chappuis B, Holzer B, et al. Mansonella perstans causing symptomatic hypereosinophilia in a missionary family. Travel Med Infect Dis 2006, 4:275-280.
203. Asio SM, Simonsen PE, Onapa AW Mansonella perstans: safety and efficacy of ivermectin alone, albendazole alone and the two drugs in combination. Ann Trop Med Parasitol 2009, 103:31-37.
204. Bregani ER, Rovellini A, Mbaidoum N, et al. Comparison of different anthelminthic drug regimens against Mansonella perstans filariasis. Trans R Soc Trop Med Hyg 2006, 100:458-463.
205. Coulibaly YI, Dembele B, Diallo AA, et al. A randomized trial of doxycycline for Mansonella perstans infection. N Engl J Med 2009, 361:1448-1458.
206. Fischer P, Bamuhiiga J, Buttner DW Occurrence and diagnosis of Mansonella streptocerca in Uganda. Acta Tropica 1997, 63:43-55.
207. Fischer P, Buttner DW, Bamuhiiga J, et al. Detection of the filarial parasite Mansonella streptocerca in skin biopsies by a nested polymerase chain reaction-based assay. Am J Trop Med Hyg 1998, 58:816-820.
208. Fischer P, Tukesiga E, Buttner DW Long-term suppression of Mansonella streptocerca microfilariae after treatment with ivermectin. J Infect Dis 1999, 180:1403-1405.
209. Fischer P, Bamuhiiga J, Buttner DW Treatment of human Mansonella streptocerca infection with ivermectin. Trop Med Int Health 1997, 2:191-199.
210. Adami YL, Moraes MA, Lanfredi RM, et al. An atypical microfilaria in blood samples from inhabitants of Brazilian Amazon. Parasitol Res 2008, 104:95-99.
211. Bartoloni A, Cancrini G, Bartalesi F, et al. Mansonella ozzardi infection in Bolivia: prevalence and clinical associations in the Chaco region. Am J Trop Med Hyg 1999, 61:830-833.
212. McNeeley DF, Raccurt CP, Boncy J, et al. Clinical evaluation of Mansonella ozzardi in Haiti. Trop Med Parasitol 1989, 40:107-110.
213. Post RJ, Adams Z, Shelley AJ, et al. The morphological discrimination of microfilariae of Onchocerca volvulus from Mansonella ozzardi. Parasitology 2003, 127:21-27.
214. Gonzalez AA, Chadee DD, Rawlins SC Single dose of ivermectin to control mansonellosis in Trinidad: a four-years follow-up study. Trans R Soc Trop Med Hyg 1998, 92:570-571.
215. Orihel TC, Eberhard ML Zoonotic filariasis. Clin Microbiol Rev 1998, 11:366-381.
216. McCall JW, Genchi C, Kramer LH, et al. Heartworm disease in animals and humans. Adv Parasitol 2008, 66:193-285.
217. Lee AC, Montgomery SP, Theis JH, et al. Public health issues concerning the widespread distribution of canine heartworm disease. Trends Parasitol 2010, 26:168-173.
218. Otranto D, Brianti E, Gaglio G, et al. Human ocular infection with Dirofilaria repens (Railliet and Henry, 1911) in an area endemic for canine dirofilariasis. Am J Trop Med Hyg 2011, 84:1002-1004.
219. Bimi L Potential vector species of Guinea worm (Dracunculus medinensis) in Northern Ghana. Vector Borne Zoonotic Dis 2007, 7:324-329.
220. Bimi L, Freeman AR, Eberhard ML, et al. Differentiating Dracunculus medinensis from D. insignis, by the sequence analysis of the 18S rRNA gene. Ann Trop Med Parasitol 2005, 99:511-517.
221. Bloch P, Simonsen PE Immunoepidemiology of Dracunculus medinensis infections I. Antibody responses in relation to infection status. Am J Trop Med Hyg 1998, 59:978-984.
222. Bloch P, Simonsen PE Immunoepidemiology of Dracunculus medinensis infections II. Variation in antibody responses in relation to transmission season and patency. Am J Trop Med Hyg 1998, 59:985-990.
223. Glenshaw MT, Roy S, Ruiz-Tiben E, et al. Guinea worm disease outcomes in Ghana: determinants of broken worms. Am J Trop Med Hyg 2009, 81:305-312.
224. Rohde JE, Sharma BL, Patton H, et al. Surgical extraction of guinea worm: disability reduction and contribution to disease control. Am J Trop Med Hyg 1993, 48:71-76.
225. Issaka-Tinorgah A, Magnussen P, Bloch P, et al. Lack of effect of ivermectin on prepatent guinea-worm: a single-blind, placebo-controlled trial. Trans R Soc Trop Med Hyg 1994, 88:346-348.
226. Hunter JM Bore holes and the vanishing of guinea worm disease in Ghana's upper region. Soc Sci Med 1997, 45:71-89.
227. Ruiz-Tiben E, Hopkins DR Dracunculiasis (Guinea worm disease) eradication. Adv Parasitol 2006, 61:275-309.
228. Hochberg N, Ruiz-Tiben E, Downs P, et al. The role of case containment centers in the eradication of dracunculiasis in Togo and Ghana. Am J Trop Med Hyg 2008, 79:722-728.
229. WHO Dracunculus eradication - global surveillance summary, 2010. Wkly Epidemiol Rec 2011, 86:189-198.
230. WHO Lymphatic filariasis: Progress report 2000-2009 and strategic plan 2010-20 2010, World Health Organization, Geneva.
231. Ottesen EA Lymphatic filariasis: Treatment, control and elimination. Adv Parasitol 2006, 61:395-441.
232. Cupp EW, Sauerbrey M, Richards F Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan®) monotherapy. Acta Tropica 2011, 120(Suppl 1):S100-S108.
233. Boussinesq M Loiasis. Ann Trop Med Parasitol 2006, 100:715-731.
234. Ruiz-Tiben E, Hopkins DR Dracunculiasis (Guinea worm disease) eradication. Adv Parasitol 2006, 61:275-309.